In his plenary lecture at 2016 SABCS, Peter P. Bach, MD, MAPP, reviewed the factors contributing to escalating drug prices and the significance of drug prices in the value of a cancer treatment regimen.
Participants in a peer navigation program for patients at risk for HBOC were surveyed regarding the usefulness of the information provided, patient education, and their peer navigator. Survey results were presented at the 2016 SABCS.
An app developed to track posthospitalization progress and activity of patients with breast cancer, adding the information into patients' electronic health records in real time, was presented at SABCS 2016.
A new system appears efficacious in preventing chemotherapy-related alopecia in women with breast cancer, according to a study presented at SABCS 2016.
Women who experienced menopause-related side effects were significantly less likely to adhere to their assigned tamoxifen therapy.
Community Breast Navigation Program Improved Breast Screening Rates in Underserved African American and Latino WomenDecember 09, 2016
A community breast navigation program successfully increased mammogram screening rates among African American and Latino women, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
Live-streamed videos are a novel and forward-thinking approach for individuals to learn about end-of-life (EOL) planning and decision-making, according a study presented at the 2016 San Antonio Breast Cancer Symposium.
Patients with metastatic breast cancer have significantly diminished quality of life (QoL) compared with those without metastatic disease and those without breast cancer, a study presented at the 2016 San Antonio Breast Cancer Symposium.
History of Bilateral Salpingo-oophorectomy, Hormone Replacement Therapy Are Predictive of Breast Density at Cancer DiagnosisDecember 09, 2016
A history of surgical menopause and were receiving hormone replacement therapy are a factor in breast density, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
Study data presented at SABCS 2016 indicates that preoperative MRI is effective for detecting mammographically occult, early-stage, hormone receptor (HR)-positive contralateral breast cancer (CBC) in older patients.
Clinical breast examination (CBE) is superior to MRI for predicting pathologic complete response (pCR) in women with HER2-positive breast cancer, a study presented at the 2016 San Antonio Breast Cancer Symposium indicates.
Research presented at SABCS 2016 identified biomarkers predictive of response to trastuzumab-containing therapies in patients with HER2-positive breast cancer.
A new tool may show promise for improving clinical trial participation among black women with breast cancer, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
Results of a comparison study of radioactive seed localization and wire guided localization in patients with nonpalpable invasive breast cancer or DCIS were presented at SABCS 2016.
Patients with HER2-positive, HR-positive advanced breast cancer experience significantly improved progression-free survival when pertuzumab is added to first-line trastuzumab and an AI compared with trastuzumab and an AI alone, according to study findings presented at SABCS 2016.
A novel bromodomain-containing protein 4 inhibitor demonstrated antitumor activity in both endocrine-sensitive and endocrine-resistance breast cancer models, according to a study presented at SABCS 2016.
Investigators report on the efficacy of a structured prophylactic regimen of loperamide for 2 cycles to reduce incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer, at SABCS 2016.
In this presentation at SABCS 2016, researchers present an evaluation of the ability of the PAM50 HER2-enriched intrinsic subtype to predict pathologic complete response in the breast in patients who received 18 weeks of neoadjuvant dual HER2 blockade.
In a poster presentation at SABCS 2016, researchers reported on the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of CINV in patients receiving highly or moderately emetogenic chemotherapy.
Researchers found that temporary pretreatment with LDA may protect normal breast tissue during chemotherapy for breast cancer in patients undergoing breast-conserving therapy, according to a study presented at SABCS 2016.
A study presented at SABCS 2016 reports on the incidence of complications and costs in women who undergo breast-conserving surgery for breast carcinoma.
Researchers report their study findings on the safety of omitting radiotherapy after breast-conserving surgery, sentinel node biopsy, and adjuvant endocrine therapy in older patients with early breast cancer and favorable histopathology at SABCS 2016.
Researchers investigated the potential of PID fluorescent nanoparticles, a novel detection technique to visualize and quantify protein in clinical samples, for quantifying HER2 protein expression in breast cancer, according to a study presented at SABCS 2016.
Robustness of dichotomous assessment is important when evaluating stromal features of ductal carcinoma in situ (DCIS), according to a study presented at SABCS 2016.
Research presented at 2016 SABCS showed whether RANKL inhibition could reduce the risk for developing breast cancer in BRCA1 mutation carriers.
Bi-allelic inactivation of BRCA1 and BRCA2 are frequent events in BRCA1 breast cancers and BRCA2 breast cancers, respectively, according to a study presented at SABCS 2016.
In this study presented at SABCS 2016, investigators determined the association between higher TIL levels and overall survival in patients with advanced HER2-positive breast cancer treated with docetaxel plus trastuzumab in combination with pertuzumab or placebo.
Researchers assessed the relationship between immune gene expression and genomic complexity in TNBC in a study presented at SABCS 2016.
Today at SABCS 2016 investigators presented results of the NRG Oncology/NSABP B-42, a double-blind phase 3 trial to determine whether extended treatment with letrozole would improve disease-free survival in certain women with HR-positive breast cancer.
At SABCS 2016, researchers presented study findings demonstrating whether neoadjuvant treatment, PARPi-7, BRCAness, and MP1/2 predict response to veliparib plus carboplatin therapy in patients with high-risk breast cancer.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|